Present address: The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, 2056, Victoria, Australia.
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Version of Record online: 15 JUL 2011
© 2011 The Authors. Clinical and Experimental Immunology © 2011 British Society for Immunology
Clinical & Experimental Immunology
Volume 166, Issue 1, pages 1–15, October 2011
How to Cite
Menu, P. and Vince, J. E. (2011), The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clinical & Experimental Immunology, 166: 1–15. doi: 10.1111/j.1365-2249.2011.04440.x
- Issue online: 12 SEP 2011
- Version of Record online: 15 JUL 2011
- Accepted for publication 2 June 2011
- innate immunity;
While interleukin (IL)-1β plays an important role in combating the invading pathogen as part of the innate immune response, its dysregulation is responsible for a number of autoinflammatory disorders. Large IL-1β activating platforms, known as inflammasomes, can assemble in response to the detection of endogenous host and pathogen-associated danger molecules. Formation of these protein complexes results in the autocatalysis and activation of caspase-1, which processes precursor IL-1β into its secreted biologically active form. Inflammasome and IL-1β activity is required to efficiently control viral, bacterial and fungal pathogen infections. Conversely, excess IL-1β activity contributes to human disease, and its inhibition has proved therapeutically beneficial in the treatment of a spectrum of serious, yet relatively rare, heritable inflammasomopathies. Recently, inflammasome function has been implicated in more common human conditions, such as gout, type II diabetes and cancer. This raises the possibility that anti-IL-1 therapeutics may have broader applications than anticipated previously, and may be utilized across diverse disease states that are linked insidiously through unwanted or heightened inflammasome activity.